Answers are grounded in this paper and cite their sources.
Novel platform demonstrates improved nuclear transport and membrane fusion in targeted cancer cells, indicating potential for effective genome editing.
Therapeutic Genome Editing In article number (e11362), Jounghyun Yoo, Seung Woo Cho, Jinmyoung Joo, and co-workers introduced a FAST-CRISPR (Fusogenic Association and Secured Transfection of CRISPR/Cas9) platform engineered for rapid cytosolic delivery of CRISPR/Cas9 ribonucleoproteins. By mediating direct membrane fusion to bypass endocytic pathways, it enables rapid cytosolic delivery and nuclear transport of ribonucleoproteins. This strategy successfully triggers targeted cancer cell apoptosis, establishing a promising non-viral genome editing tool.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: